All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
|571||Poster Presentation||ANV419 is a novel CD122-selective IL-2/anti-IL-2 antibody fusion protein with potent CD8 T cell and NK cell stimulatory function in vitro and in vivo||Christoph Huber, PhD; Andreas Katopodis, PhD; Barbara Branetti; Jean-Michel Rondeau; Simone Popp; Catherine Regnier; Daniel Kaiser;||Immune-stimulants and immune modulators||Antibody; Cytokine; Immune adjuvant; Immune toxicity; NK/NK T cell; Regulatory T cell (Treg cell); T cell|